The Union Ministry of Health and Family Welfare has proposed stricter microbial monitoring standards for sterile pharmaceutical manufacturing facilities in India, seeking to align domestic requirements with World Health Organization (WHO) guidelines.
The proposal involves amendments to Schedule M of the Drugs Rules, 1945, through draft notification G.S.R. 953(E), dated October 28, 2026. The Ministry announced the proposal on November 4, 2026.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: Proposed revision of microbial contamination monitoring limits under Schedule M for sterile pharmaceutical manufacturing.
Location: India.
Authority/Organisation: Union Ministry of Health and Family Welfare.
Action Taken: Issued draft notification G.S.R. 953(E) to align Grade A monitoring requirements with WHO guidelines.
Impact: The proposal aims to strengthen contamination control and quality assurance in sterile medicine manufacturing.
The proposed changes focus on Grade A clean areas, which are critical zones in sterile medicine manufacturing where exposed products, containers and sterilised components are handled. Maintaining strict environmental controls in these areas is essential to preventing microbial contamination during production.
Under the draft amendment, the Ministry proposes replacing Table 3 under Requirement 4, paragraph 4.9 of Part II of Schedule M. The revised table would establish recommended microbial contamination limits for Grade A, B, C and D manufacturing environments.
The most significant change concerns Grade A areas. The proposed standard specifies no microbial growth for the monitored parameters, including air samples, settle plates, contact plates and glove prints. This reflects the stricter approach outlined in WHO Technical Report Series No. 1044, Annexure 2, covering Good Manufacturing Practices for sterile pharmaceutical products.
Editorial Analysis
Why This Matters
Sterile medicines require particularly strict manufacturing conditions because microbial contamination can create serious quality and safety concerns. Grade A clean areas are among the most critical controlled environments in pharmaceutical facilities. They are used for operations involving exposed sterile products and components, making environmental monitoring an important part of quality assurance. The proposed no-growth standard would establish a stricter monitoring expectation for these areas. Aligning Indian requirements with WHO guidance could also help manufacturers follow internationally recognised practices. For patients, stronger manufacturing controls are important because the quality of sterile medicines depends not only on the ingredients used but also on the conditions under which products are manufactured, handled and released.
The proposed table also specifies monitoring limits for other cleanroom grades. For Grade B areas, the recommended limits are 10 CFU per cubic metre for air samples, 5 CFU per four hours for settle plates, 5 CFU per contact plate and 5 CFU per glove. For Grade C, the corresponding limits are 100, 50 and 25, while Grade D limits are 200, 100 and 50. The table does not prescribe glove-print limits for Grade C and D.
CFU, or colony-forming units, is a measurement used to estimate the number of viable microorganisms detected in a sample.
The proposed revision aims to reduce differences between India's Schedule M requirements and WHO standards for sterile pharmaceutical production. It is intended to strengthen contamination control and improve quality assurance in manufacturing environments where even small lapses can affect product safety.
The draft notification has been issued under the Drugs and Cosmetics Act, 1940, following consultation with the Drugs Technical Advisory Board. The Ministry has invited objections and suggestions from affected stakeholders and members of the public.
The proposed rules will be considered after the expiry of 30 days from the date on which copies of the Gazette containing the draft become available to the public. The draft also states that the amended rules will come into force on a date specified by the Government at the time of final publication.
This means the proposal is not yet a final, implemented regulatory requirement. The final notification and any changes made after consultation will determine the requirements that manufacturers must follow.
For India's pharmaceutical sector, the proposed standards are relevant to sterile medicines, including injectable and ophthalmic products. Stronger environmental monitoring can support manufacturing quality and help maintain confidence in medicines produced for domestic use and international markets.
